April 8, 2013 Arno Therapeutics Reports Activated Progesterone Receptors Predictive of Response to Onapristone
March 19, 2013 Arno Therapeutics Engages The Ruth Group for Investor Relations and Public Relations Counsel
December 19, 2012 Arno Therapeutics Completes $14.9 Million Financing To Advance Lead Clinical Compounds
December 5, 2012 Arno Therapeutics Reports Findings of New Diagnostic Technique the Potential to Identify Patients with Cancer Who May Respond to Treatment with Onapristone
November 9, 2012 Arno Therapeutics Reports Progress in Development of Clinical Biomarkers to Support Treatment of Breast Cancer with Onapristone
October 16, 2012 Kite Pharma Partners with the National Cancer Institute to Develop Novel Cellular Immunotherapy Clinical Products
February 21, 2012 Arno Therapeutics Receives Two Orphan-Drug Designations for AR-42 in Treatment of Central-Nervous-System Tumors
February 14, 2012 Arno Therapeutics Announces Exclusive Licensing Agreement with Invivis Pharmaceuticals to Develop Cancer Drug
June 27, 2011 Arno Therapeutics Names Alexander Zukiwski, M.D., Vice President and Chief Medical Officer
June 23, 2011 Arno Therapeutics Reports Positive Interim Results from Glioblastoma Study; Phase II Enrollment to Continue
May 26, 2011 Tigris Pharmaceuticals Initiates Randomized Phase 2 Study of AFP-464 in ER-Positive Breast Cancer Patients
April 28, 2011 Arno Therapeutics Announces the Appointment of Mr. Glenn Mattes as President and Chief Executive Officer
March 31, 2011 Nile Therapeutics Receives Fast Track Designation for Cenderitide for Post-Acute Indication
March 9, 2011 Kite Pharma Raises $15 Million in Initial Round of Financing and Appoints David Bonderman to Board of Directors
February 28, 2011 Nile Therapeutics to Collaborate with Medtronic on Clinical Development of Cenderitide for Heart Failure and Renal Disease
